Aquestive Therapeutics Management
Management criteria checks 2/4
Aquestive Therapeutics' CEO is Dan Barber, appointed in May 2022, has a tenure of 2.5 years. total yearly compensation is $2.50M, comprised of 24% salary and 76% bonuses, including company stock and options. directly owns 1.52% of the company’s shares, worth $6.24M. The average tenure of the management team and the board of directors is 2.3 years and 2.2 years respectively.
Key information
Dan Barber
Chief executive officer
US$2.5m
Total compensation
| CEO salary percentage | 24.0% |
| CEO tenure | 2.5yrs |
| CEO ownership | 1.5% |
| Management average tenure | 2.3yrs |
| Board average tenure | 2.2yrs |
Recent management updates
Recent updates
Aquestive: Rare Opportunity With Dual Platform Strategy
Nov 05Market Participants Recognise Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Revenues Pushing Shares 27% Higher
Sep 07
Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025
Aug 20Rainbows and Unicorns: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Became A Lot More Optimistic
Aug 11What Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 30% Share Price Gain Is Not Telling You
Jul 24Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
May 22Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024
Apr 09Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up
Feb 28Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1
Jan 19Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Popularity With Investors Is Under Threat From Overpricing
Jan 05Aquestive Therapeutics, Inc. (NASDAQ:AQST) Surges 63% Yet Its Low P/S Is No Reason For Excitement
Apr 17Aquestive Therapeutics receives positive FDA response for AQST-109 epinephrine for severe allergic reaction
Oct 11Aquestive Therapeutics, Pharmanovia ink licensing & supply pact for Libervant buccal film
Sep 28Aquestive Therapeutics: FDA Stymies Libervant Launch
Sep 05Aquestive Therapeutics: A First Take
Aug 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$35m |
| Jun 30 2024 | n/a | n/a | -US$26m |
| Mar 31 2024 | n/a | n/a | -US$29m |
| Dec 31 2023 | US$2m | US$600k | -US$8m |
| Sep 30 2023 | n/a | n/a | -US$12m |
| Jun 30 2023 | n/a | n/a | -US$23m |
| Mar 31 2023 | n/a | n/a | -US$33m |
| Dec 31 2022 | US$1m | US$542k | -US$54m |
| Sep 30 2022 | n/a | n/a | -US$71m |
| Jun 30 2022 | n/a | n/a | -US$73m |
| Mar 31 2022 | n/a | n/a | -US$69m |
| Dec 31 2021 | US$1m | US$424k | -US$71m |
| Sep 30 2021 | n/a | n/a | -US$62m |
| Jun 30 2021 | n/a | n/a | -US$64m |
| Mar 31 2021 | n/a | n/a | -US$54m |
| Dec 31 2020 | US$840k | US$410k | -US$56m |
| Sep 30 2020 | n/a | n/a | -US$48m |
| Jun 30 2020 | n/a | n/a | -US$50m |
| Mar 31 2020 | n/a | n/a | -US$68m |
| Dec 31 2019 | US$1m | US$389k | -US$66m |
| Sep 30 2019 | n/a | n/a | -US$68m |
| Jun 30 2019 | n/a | n/a | -US$64m |
| Mar 31 2019 | n/a | n/a | -US$80m |
| Dec 31 2018 | US$2m | US$319k | -US$61m |
| Sep 30 2018 | n/a | n/a | -US$61m |
| Jun 30 2018 | n/a | n/a | -US$38m |
| Mar 31 2018 | n/a | n/a | -US$8m |
| Dec 31 2017 | US$899k | US$300k | -US$14m |
Compensation vs Market: Dan's total compensation ($USD2.50M) is about average for companies of similar size in the US market ($USD2.24M).
Compensation vs Earnings: Dan's compensation has increased whilst the company is unprofitable.
CEO
Dan Barber (48 yo)
2.5yrs
Tenure
US$2,496,141
Compensation
Mr. Daniel Barber, also known as Dan, is the Chief Executive Officer, President and Director at Aquestive Therapeutics, Inc. since May 17, 2022 and served as its Senior Vice President since April 2014 unti...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 2.5yrs | US$2.50m | 1.52% $ 6.2m | |
| Chief Financial Officer | 3.9yrs | US$1.12m | 0.43% $ 1.8m | |
| General Counsel | 6.2yrs | US$1.19m | 0.52% $ 2.2m | |
| Chief Operating Officer | 2yrs | no data | 0.25% $ 1.0m | |
| Chief Innovation & Technology Officer | 9.9yrs | US$810.02k | 1.08% $ 4.4m | |
| Chief Science Officer | no data | no data | 0.28% $ 1.2m | |
| Senior Vice President of Sales & Marketing | less than a year | no data | 0.027% $ 112.8k | |
| Senior Vice President of Information Technology & Human Resources | 1.7yrs | no data | 0.26% $ 1.1m | |
| Chief Medical Officer | no data | no data | no data | |
| Chief Medical Officer | 1.4yrs | no data | 0.28% $ 1.1m | |
| VP of Finance | no data | no data | no data |
2.3yrs
Average Tenure
58yo
Average Age
Experienced Management: AQST's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 2.5yrs | US$2.50m | 1.52% $ 6.2m | |
| Independent Director | 2.3yrs | US$145.23k | 0% $ 0 | |
| Independent Chairman of the Board | 17.7yrs | US$150.77k | 0.082% $ 338.6k | |
| Independent Director | 3.8yrs | US$137.69k | 0% $ 0 | |
| Independent Vice Chairman of the Board | 20.8yrs | US$137.23k | 0.11% $ 448.7k | |
| Independent Director | 3.8yrs | US$121.78k | 0% $ 0 | |
| Member of Scientific Advisory Board | 2.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.2yrs | no data | no data |
2.2yrs
Average Tenure
61yo
Average Age
Experienced Board: AQST's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.